MARATTO

preprint

Novel Furan-2(3H)-one derivatives as promising anticancer agents against liver and breast cancers cell lines: Green Synthesis, Spectroscopic analysis, in Vitro Antiproliferative Activity, and DFT study

2024Open accessAin Shams University

Abstract

<title>Abstract</title> Some new biologically active heterocyclic compounds were synthesized upon green reaction of <bold>(</bold>Z)-3-(benzo[d][1,3]dioxol-5-ylmethylene)-5-phenylfuran-2(3<italic>H</italic>)-one (L)with different electrophilic and nucleophile reagents under ultrasonic irradiation. The electronic structure of synthesized prepared materials was elucidated using FTIR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, and X-ray diffraction, elemental analysis, and melting point. The new compounds were examined for <italic>invitro</italic> ant proliferative action towards HepG-2, HCT116, MCF-7, and the normal human skin fibroblasts (BJ-1) cell lines. The results showed that: five investigated compounds could be considered as good selective ant proliferative candidate drugs for only human liver cancer as their effects on this cancer type are much more toxic compared to their toxicity on the human healthy cells. DFT Study of the new compounds showed that pyrrolone derivatives <bold>L3, L4, LN</bold>, and azapyrrolone <bold>L5</bold> (pyrimidinone) have the maximum electron transfer for inhibition for cancer cells.

Research topics

  • Synthesis and biological activity
  • Synthesis of Organic Compounds
  • Click Chemistry and Applications

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21203/rs.3.rs-4926797/v1

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.